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INTRODUCTION
Over the last few decades, improvements in surgical techniques
and (chemo)radiotherapy have increased the survival rate in
patients with lung cancer (1). Despite this, the survival of patients
with locally advanced non-small cell lung cancer (NSCLC) remains
poor, with a 5-year overall survival (OS) of 15% for stage III
NSCLC patients treated with concurrent chemoradiotherapy (2).
Prior studies have suggested that a higher tumor dose can
result in increased locoregional control, and consequently in
an improved disease-specific survival (3, 4). Different strate-
gies to escalate the dose to the primary target volume have
been studied, i.e., isotoxic dose enhancement, hyperfractiona-
tion, or dose-rescaling on an individual basis (5–7). However, the
tumor-surrounding healthy tissues (healthy lung, heart, mediasti-
nal structures, spinal cord, and brachial plexus) are often dose
limiting.
Even though modern radiotherapy techniques (e.g., 3D con-
formal radiotherapy; 3D-CRT, or intensity-modulated radiation
therapy; IMRT) decrease dose to surrounding tissues compared
with 2D techniques, particle beam therapy may offer an even
greater advantage. The favorable properties of charged particles in
terms of dose distribution and radiobiological effectiveness make
it an option worth investigating for the treatment of NSCLC.
Treatment with protons or carbon ions can enable dose esca-
lation beyond what can be achieved with the different photon
techniques (8). There are, however, several difficulties with the
delivery of particle beams to a tumor in the lung. These include
the fact that the tumor and other anatomy may be moving, that
variations exist in the water equivalent thickness of the beam path,
and that the range uncertainties associated with pencil beam scan-
ning (PBS) techniques are particularly sensitive to motion and
setup errors (9, 10).
The aim of this article is to systematically review the currently
available evidence on the clinical effectiveness and in silico com-
parative planning studies of particle therapy for the treatment of
NSCLC. The technical issues and dosimetric uncertainties with
respect to thoracic particle therapy are also discussed.
METHODS
The PubMed database was searched by two researchers to identify
studies about particle therapy for NSCLC. Search items were lung,
proton, particle, hadron, carbon, cancer, tumor, neoplasm, ther-
apy, treatment, radiation therapy, radiotherapy, irradiation, and
NSCLC. The search terms were used in different combinations
and plural forms, and the search was limited to articles in Eng-
lish. References were screened for additional articles. Three types
of studies were included: studies reporting on the outcomes of
particle therapy for NSCLC, studies comparing dose distributions
in (in silico) planning studies, and studies reporting on technical
issues with particle therapy for NSCLC.
RESULTS
CLINICAL OUTCOME
All the studies reporting on clinical outcome of particle therapy
for NSCLC were published by one of the following centers treating
NSCLC patients with particle beams: the Loma Linda University
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Medical Center (LLUMC, Loma Linda, CA, USA), the MD Ander-
son Cancer Center (MDACC, Houston, TX, USA), the Proton
Medical Research Center (PMRC, Tsukuba, Japan), the Hyogo Ion
Beam Medical Center (HIBMC, Tatsuno, Japan), and the National
Cancer Center Hospital East (NCCHE, Chiba, Japan). Due to
overlapping study periods from the same institutions reporting
on the same disease stages, it is reasonable to assume that the
same patients were analyzed in multiple reports. This was, how-
ever, not always obvious because follow-up periods and patient
numbers differed. Therefore, it was decided to include all the pub-
lished studies in this review. In instances where the studied patient
cohort was identical (same number of patients, patient character-
istics, and follow-up period), only the most recent study reporting
on clinical outcome was selected. Study characteristics are summa-
rized in Table 1 (early-stage NSCLC) and Table 2 (advanced-stage
NSCLC).
Early-stage NSCLC
Study descriptions. Fourteen studies investigated particle ther-
apy for early-stage (stage I or II) NSCLC. The patients included
were either medically inoperable or refused surgery, since surgery
is still regarded as the first choice for treatment of Stage I NSCLC
(11–13). Six studies reported the outcome of patients treated
with protons only (14–19), four used carbon ions only (20–23),
two studies reported outcome for both carbon ions and protons
(24, 25), and two studies treated patients with a combination of
photons and protons (26, 27). The most recent study is that of
Kanemoto et al. (19). The researchers retrospectively evaluated
disease control rates after high-dose proton beam therapy (PBT)
in 74 patients with stage I NSCLC, with tumor doses of 66 Gy-
equivalent (GyE) in 10–12 fractions for peripheral tumors (74%
of all tumors) and 72.6 GyE in 22 fractions for centrally located
tumors. Another retrospective study from the same center (with
different investigators), evaluated the outcome of PBT for 55 med-
ically inoperable patients with stage I NSCLC, using the same total
dose and fractionation (17). The study periods of both studies
overlap, making it reasonable to assume that the patients included
in the study by Nakayama et al. (17) were also assessed by the
Kanemoto group (19).
In both studies by Iwata et al. (24, 25), early-stage NSCLC
patients were treated with either carbon ions or protons. In their
first report, the authors reported the outcome for 80 stage I NSCLC
patients treated with 60–80 GyE protons or 52.8 GyE carbon ions
during the period 2003–2007 (24). After restaging based on the
AJCC seventh edition of the TNM classification and a longer inclu-
sion and follow-up period (median 51 months), they analyzed the
outcome for 70 cT2a/2bN0M0 NSCLC patients in a second study
(25). Some patients in the cohort were, therefore, included in both
the studies. The choice of particle type was based on beam avail-
ability (during part of the study,only proton beams were available),
and if both particle types were available, a choice was made after
comparison of dose–volume histograms for both modalities.
The American group of Bush et al. (14, 18, 26) has performed
three studies on proton beam irradiation for early-stage NSCLC
in patients with contraindications to surgery or patients refusing
surgery. In their first study, they treated 19 patients with insuffi-
cient pulmonary reserve or severe cardiac dysfunction with 51 GyE
of PBT to the gross tumor volume (GTV). In 18 patients with suf-
ficient cardiopulmonary function, 45 Gy in 1.8 Gy fractions was
delivered with photon irradiation, followed by a proton beam
boost to the GTV of 28.8 GyE in 1.8 GyE fractions. In 2004 and
2013, updates of the first trial were published, focusing on stage
I NSCLC patients treated with proton therapy only (14, 18). The
study published in 2013 investigated the outcome of 111 early-
stage NSCLC patients, with dose escalation from 51 GyE in 10
fractions to 70 GyE in 10 fractions during the course of the study
(18). Nihei et al. (15) treated 37 stage I patients with PBT in Chiba,
Japan. Ten of the included patients were enrolled in an earlier dose
escalation study and all patients received 70–94 GyE in 20 fractions
(fraction dose 3.5–4.7 GyE).
The use of carbon ions for early-stage NSCLC was investi-
gated in four phase II studies by Japanese researchers in a similar
study population (20–23). Sugane et al. (23) focused on patients
of 80 years or older within the study cohorts of Miyamoto et al.
(21, 22). The patients received 52.8 GyE (stage IA) or 60 GyE (stage
IB) in four fractions during 1 week, or (if treated prior to 2000)
72 GyE in 9 fractions over 3 weeks.
Overall survival and local control. The outcome of the selected
studies for early-stage NSCLC is summarized in Table 3. The
retrospective study by Nakayama et al. (17) observed 2-year OS
and local control rates of 97.8 and 97.0%, respectively. How-
ever, the study had a relatively short follow-up period (median
17.7 months). No difference in local recurrence between tumors
located centrally or peripherally in the lung was observed.
Kanemoto et al. (19) reported a 3-year OS of 76.7% and a 3-year
local control rate of 81.8% (stage IA 86.2%, stage IB 67%) with a
median follow-up period of 31.0 months. The 3-year local control
rate was significantly better for peripherally located tumors: 88.4
versus 63.9% for centrally located tumors.
In their first study in 2010, Iwata et al. (24) reported the out-
come for 80 patients treated with either protons or carbon ions
with a median follow-up of 30.5 months. They observed 3-year
OS and local control rates of 75 and 82%, respectively. No signif-
icant difference in outcome was observed between the different
treatment protocols. The authors also published the long-term
outcome for cT2a and cT2b NSCLC patients (25). They reported a
4-year local control rate of 75%, and overall and progression-free
survival rates of 58 and 46%, respectively. No significant differ-
ences were observed based on T stage. The survival of the operable
patients was better than for the medically inoperable patients.
Studies reporting on the use of carbon ions for early-stage lung
cancer demonstrate 5-year OS and local control rates of 45 and
90%, respectively (21), and of 30.7 and 95.8% (23) for patients
aged 80 years or older.
Toxicity. The toxicity of PBT for early-stage NSCLC was found
to be low, with the percentage of acute and late CTC grade ≥2
adverse events generally <10%. This is not a surprising outcome,
since stereotactic body radiation therapy (SBRT) with photons
for stage I NSCLC also has a generally favorable toxicity profile
(13). Mainly for peripheral tumors, few treatment related compli-
cations have been reported (28). The treatment of central tumors
located close to vulnerable mediastinal structures, however, can
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Table 1 | Study descriptions early stage NSCLC.
Study (characteristics);
location
Beam, energy,
technique
Chemotherapy Fractionation schedule,
TTD/n or fr/OTT
Patient selection
criteria/risk factors
Stage distribution
PROTON BEAM ONLY
Bush et al. (26)
(prospective, n=37);
U.S. Loma Linda
Proton No 51 GyE/10 fr/2 weeks PBT NSCLC stage I–IIIA; medically
inoperable/refused surgery
Stage I, 27; Stage II,
2; Stage IIIA, 8Photon+proton
PSc
Photons 45 Gy/25fr+protons,
28.8 GyE/16 fr/5 weeks
Shioyama et al. (27)
(retrospective, n=51);
Japan, Tsukuba
Proton, 250 MeV,
PSc (n=33)
Photon+proton
(n=18)
6 patients prior
chemotherapy
(all advanced
stages)
Median 76 Gy (range 49-93 Gy),
median fr dose 3.0 Gy (range
2–6 Gy), median OTT 43 days
NSCLC, medically
inoperable/refused surgery
Stage IA/IB, 9/19;
Stage IIA/IIB, 3/6;
Stage IIIA/IIIB, 8;
Stage IV, 1, recurrent
disease, 5.
Bush et al. (14)
(Phase II, n=68); U.S.
Loma Linda
Proton, PSc No 51 GyE/10 fr/2 weeks (n=22);
60 GyE/10 fr/2 weeks (n=46)
NSCLC stage I, medically
inoperable (n=63)/refused
surgery (n=5)
Stage IA, 29;
Stage IB, 39
Nihei et al. (15)
(Retrospective, n=37);
Japan, Chiba
Proton, 150 or
190 MeV, PSc
No 70 GyE/20 fr/4–5 weeks (n=3);
80 GyE/20 fr/4–5 weeks (n=17);
88 GyE/20 fr/4–5 weeks (n=16);
94 GyE/20 fr/4–5 weeks (n=1)
NSCLC stage I; medically
inoperable (n=23)/refused
surgery (n=14), tumor
size≤5 cm, pO2 ≥60 torr,
Zubrad PS 0-2
Stage IA, 17;
Stage IB, 20
Hata et al. (16)
(prospective, n=21),
Japan, Tsukuba
Proton,
155-200 MeV,
PSc
No 50 GyE/10 fr/2 weeks (n=3);
60 GyE/10 fr/2 weeks (n=18)
NSCLC stage I, medically
inoperable (n=9)/refused
surgery (n=12), ECOG PS
0–2, no previous RT or
chemotherapy for NSCLC
Stage IA, 11;
Stage IB 10
Nakayama et al. (17)
(retrospective, n=55)
(58 tumors) Japan,
Tsukuba
Proton,
155–250 MeV,
PSc
No Peripheral tumors 66 GyE/10
fr/2 weeks (n=41), central
tumors 72.6 GyE/22 fr/4.5 weeks
(n=17)
NSCLC stage I; EORTC PS
0–2, medically inoperable
(n=52)/refused surgery
(n=3), Exclusion: pleural
effusion, tumor close to
stomach/esophagus
Stage IA, 30;
Stage IB, 28
Bush et al. (18)
(Phase 2, n=111); U.S.
Loma Linda
Proton, PSc No Dose escalation during study,
51 GyE/10 fr/2 weeks (n=29),
60 GyE/10 fr/2 weeks (n=56),
70 GyE/10 fr/2 weeks (n=26)
NSCLC stage I, medically
inoperable/refused surgery
Stage IA, 47;
Stage IB, 64
Kanemoto et al. (19)
(Retrospective, n=74,
80 tumors), Japan,
Tsukuba
Proton,
155–250 MeV,
PSc
No Peripheral tumors 66 GyE/10–12
fr/2–2.5 weeks (n=59), central
tumors 72.6 GyE/22 fr/4.5 weeks
(n=21)
NSCLC stage I Stage IA, 59;
Stage IB, 21
C-ION (COMBINEDWITH PROTON BEAM)
Iwata et al. (24)
(retrospective, n=80),
Japan, Hyogo
Proton 150 MeV,
PSc
C-ion 320 MeV,
PSc
No Proton: 80 GyE/20 fr/4 weeks
(n=20), 60 GyE/10 fr/2 weeks
(n=37),
C-ion: 52.8 GyE/4 fr/1 week
(n=23)
NSCLC stage I, medically
inoperable (n=47)/refused
surgery (n=43), WHO PS 0–2,
no history lung cancer or
previous chest RT/chemo
Stage IA, 42;
Stage IB, 38
Iwata et al. (25)
{retrospective [partially
subgroup of cohort
Iwata (24)], n=70},
Japan, Hyogo
Proton 150 MeV,
PSc
C-ion 320 MeV,
PSc
No Proton: 80 GyE/20 fr/4 weeks
(n=14), 60 GyE/10 fr/2 weeks
(n=20), 66 GyE/10 fr/2 weeks
(n=8), 70.2 GyE/26 fr/5.5 weeks
(n=1)
NSCLC cT2a/T2bN0M0,
medically inoperable
(n=40)/refused surgery
(n=30), WHO PS 0–2, no
history lung cancer or previous
chest RT/chemotherapy
Stage IB, 47;
Stage IIA, 23
(Continued)
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Table 1 | Continued
Study (characteristics);
location
Beam, energy,
technique
Chemotherapy Fractionation schedule,
TTD/n or fr/OTT
Patient selection
criteria/risk factors
Stage distribution
C-ion: 52.8 GyE/4 fr/1 week
(n=16), 66 GyE/10 fr/2 weeks
(n=8), 68.4 GyE/9 fr/2 weeks
(n=3)
Miyamoto et al. (20)
(phase I/II, n=81, 82
tumors), Japan, Chiba
C-ion, 290–350–
400 MeV,
PSc
No 59.4–95.4 GyE/18 fr/6 weeks
(n=48), 68.4–79.2 GyE/9
fr/3 weeks (n=34)
Inoperable NSCLC stage I,
WHO PS 0–2, no history of RT
to target, no prior
chemotherapy <4 weeks
Stage IA, 41;
Stage IB, 41
Miyamoto et al. (21)
(phase II, n=79),
Japan, Chiba
C-ion, 290–350–
400 MeV,
PSc
No 52.8 GyE/4 fr/1 week (IA)
60 GyE/4 fr/1 week (IB)
NSCLC stage I, medically
inoperable/refused surgery,
WHO PS 0-2, no history of RT
to target, no prior
chemotherapy <4 weeks
Stage IA, 42;
Stage IB, 37
Miyamoto et al. (22)
(phase II, n=50, 51
tumors), Japan, Chiba
C-ion, 290–350–
400 MeV,
PSc
No 72 GyE/9 fr/3 weeks Peripheral NSCLC Stage I,
WHO PS 0-2, no history of RT
to target, no prior
chemotherapy <4 weeks
Stage IA, 30;
Stage IB, 21
Sugane et al. (23)
(phase II, n=28, 29
tumors), Japan, Chiba
C-ion, 290–350–
400 MeV,
PSc
No 72.0 GyE/9 fr/3 weeks (all,
1999–2000,n=12), 60.0 GyE/4
fr/1 week (IA, n=11), 52.8 GyE/4
fr/1 week (IB, n=6)
NSCLC stage I; elderly, aged
≥80 years
Stage IA, 12;
Stage IB, 17
ECOG, Eastern Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; OTT, overall treatment time; PS, performance
score; PSc, passive scattering; RT, radiotherapy; TTD, total tumor dose;WHO,World Health Organization.
cause a higher rate of severe toxicity (29). The LungTech study
(NCT01795521) is currently recruiting patients for a phase II trial
of hypofractionated photon radiotherapy (60 Gy in 8 fractions
given on alternating days) for centrally located tumors in patients
with inoperable disease. Using PBT, Bush et al. (18) reported a
low incidence of late rib fractures (4%), and in all of the cases, the
tumor was located close to the chest wall. In contrast, other stud-
ies reported a relatively high incidence of Grade≥ 2 rib fractures
of 14–27% (19, 24, 25). In the experience of Iwata et al., the rib
fractures mainly occurred in patients treated with only one beam
portal (24, 25). These patients received a rib dose of 70–100% of
the isocenter dose.
Locally advanced NSCLC
Study descriptions. Three studies have reported on the outcome
of proton therapy for locally advanced NSCLC. The retrospective
study of Oshiro et al. (30) evaluated the outcome of patients with
stage III NSCLC after treatment with protons, without concur-
rent chemotherapy. The cohort consisted of 57 patients treated
with a median dose of 74 GyE (range 50–85 GyE) in 2 GyE frac-
tions (range 2–6.6 GyE). A respiratory gating system was used,
and patients were immobilized with a body cast. Due to patient
comorbidities, old age or patient refusal, concurrent chemother-
apy was not administered. Fourteen patients received induction
chemotherapy, however, without a tumor response. Nakayama
et al. (31) reported on 35 stage II and III NSCLC patients treated
in Tsukuba between 2001 and 2008 with protons to a median dose
of 78.3 GyE. All patients were unsuitable for (n= 31) or refused
chemotherapy or surgery (n= 4). Chang et al. (32) performed
a phase II study at MD Anderson Cancer Center on the use of
protons with concurrent chemotherapy for unresectable Stage III
non-small-cell lung cancer. Forty-four stage III NSCLC patients
were included and treated with 74 GyE using passively scattered
protons, combined with weekly carboplatin and paclitaxel. Treat-
ment simulation with four-dimensional CT was undertaken and
an internal gross tumor volume (iGTV) was defined to account
for tumor motion. Verification 4D CT scans were obtained in the
third or fourth week of treatment. In case of significant changes
regarding patient anatomy or tumor shrinkage, a new treatment
plan was constructed [see Ref. (33)].
Overall survival and local control. After a median follow-up of
22.2 months (for surviving patients), Oshiro et al. (30) reported
1- and 2-year OS rates of 65.5 and 39.4%, respectively (Table 4).
Progression-free survival and local control rates were 24.9% and
64.1% at 2 years, respectively. Distant metastases were most often
the initial sites of recurrence. Induction chemotherapy did not
have a significant effect on the OS.
For the NSCLC patients included in the study by Nakayama
et al. (31), the 2-year OS was 58.9% and the local progression-free
survival at 2 years was 65.9%. Four patients (11.4%) developed
a recurrence within the irradiated primary tumor volume, 10
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Table 2 | Study descriptions advanced-stage NSCLC.
Study (characteristics);
location
Beam, energy,
technique
Chemotherapy Fractionation schedule,
TTD/n or fr/OTT
Patient selection
criteria/risk factors
Stage distribution
PROTON BEAM ONLY
Bush et al. (26) (prospective,
n=37); U.S. Loma Linda
Proton No 51 GyE/10 fr/2 weeks NSCLC stage I–IIIA; medically
inoperable/refused surgery
Stage I, 27; Stage II, 2;
Stage IIIA, 8Photon+proton PSc Photons, 45 Gy/25 fr+protons,
28.8 GyE/16 fr/5 weeks
Shioyama et al. (27)
(retrospective, n=51); Japan,
Tsukuba
Proton, 250 MeV,
PSc (n=33)
Photon+proton
(n=18)
6 patients prior chemotherapy
(all advanced stages)
MedianTD 76 Gy (range 49–93 Gy),
median fr dose 3.0 Gy (range
2-6 Gy), median OTT 43 days
NSCLC, medically inoperable/refused
surgery
Stage IA/IB, 9/19; Stage
IIA/IIB, 3/6; Stage
IIIA/IIIB, 8; Stage IV, 1,
recurrent disease, 5.
Chang et al. (32) (phase II,
n=44), U.S., Houston
Proton, PSc Concurrent, weekly carboplatin
(2AUC)+paclitaxel (50 mg/m2)
(n=44). (neo) Adjuvant
chemotherapy allowed (n=19)
74 GyE/37fr/7.5 weeks NSCLC Stage III,
Unresectable/medically inoperable,
KPS 70-100, weight loss not >10%
during <6months before diagnosis
Stage IIIA, 21; Stage
IIIB, 23
Nakayama et al. (31)
(retrospective, n=35), Japan,
Tsukuba
Proton,
155-250 MeV, PSc
No 77 GyE/35 fr/7 weeks (n=13),
83.6 GyE/38 fr/7.5 weeks (n=7),
72.6 GyE/22 fr/4.5 weeks (n=6),
74 GyE/37 fr/7.5 weeks (n=3),
other (n=6)
NSCLC Stage II/III, medically
inoperable/refused surgery, EORTC
PS 0–2, unsuitable for/refusal
chemotherapy. Exclusion: pleural
effusion, tumor close to
stomach/esophagus
Stage IIA, 2; IIB, 3;
Stage IIIA, 12, Stage
IIIB, 18
Xiang et al. (34) (prospective,
n=84), U.S. Houston
Proton, PSc Concurrent, weekly carboplatin
(2AUC)+paclitaxel (50mg/m2)
(n=84). (neo) Adjuvant
chemotherapy allowed (n=22)
74 GyE/37/7.5 weeks Stage III NSCLC, unresectable,
availability of pre- and post-treatment
PET-CT images
NR
Oshiro et al. (30)
(retrospective, n=57), Japan,
Tsukuba
Proton, 200 MeV,
PSc
No concurrent chemotherapy,
induction chemotherapy: n=14
Median 74 GyE (50-84.5 GyE),
median fr dose 2.0 GyE
(2.0–6.6 GyE)
Stage III NSCLC Stage IIIA, 24;
Stage IIIB, 33
AUC, area under the curve; EORTC, European Organization for Research and Treatment of Cancer; KPS, Karnofsky Performance Status; NR, not reported; PS, performance score; PSc, passive scattering;
TTD, total tumor dose.
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Table 3 | Study outcomes early stage NSCLC.
Study (characteristics);
location
FU OS LC DM PFS Toxicity
PROTON BEAM ONLY
Bush et al. (26) (prospective,
n=35); U.S. Loma Linda
Median 14 months
(range 3–45)
2 years 31% (Stage I: 39%) 2 years 87% 14%a 2 years 63% (Stage
I: 86%)
G2 RP: 5.7%
Shioyama et al. (27) (retrospective,
n=51); Japan, Tsukuba
Median 30 months
(range 18–153)
2 years 62%, 5 years 29% 5 years 57% (Stage IA
89%, IB 39%)
16%a 5 years 37% (Stage
IA 89%, IB 17%)
Acute: lung tox ≤G1: 92%, G2: 6%,
G3: 2%2 years Stage I/II: 55%,
Stage IA 88%, IB 47%
5 years Stage I/II 23%,
IA 70%, IB 16%
Bush et al. (14) (Phase II, n=68);
U.S. Loma Linda
At least 12 months 3 years 44%: 51 GyE: 27% 3 years 74% (Stage IA:
87%, IB: 49%)
3 years 31% 3 years 72% NR
60 GyE: 55%
Nihei et al. (15) (Retrospective,
n=37); Japan, Chiba
Median 24 months
(range 3–62)
2 years 84% 1 years 91%, 2 years
80%
19%a 1 year 73%, 2 years
58%
Acute: G1: 84% (mostly dermatitis)
No ≥grade 2
Late: lung toxicity
(pneumonitis/pleural effusion): G2:
8% or G3: 8%
Hata et al. (16) (prospective, n=21),
Japan, Tsukuba
Median 25 months
(range 10–54)
2 years 74% (Stage IA 100%,
IB 47%)
2 years 95% (Stage IA
100%, IB 90%)
19%a 2 years 79% (Stage
IA 89%, IB 70%)
Acute: hematological G1–2: 14%.
Dermatitis G1: 19%, RP G2: 5%
Late: G2: 10% (subcutaneous
induration/myositis)
Nakayama et al. (17) (retrospective,
n=55) (58 tumors) Japan, Tsukuba
Median 17.7 months
(range 1.4–53.3)
2 years 97.8% 2 years 97% 0% 2 years 88.7%,
3 years 78.9%
Acute: lung (pneumonitis) G1: 25.4%,
G2: 3.6%, G3: 3.6%
Late: rib fracture: 1.8%
Bush et al. (18) (phase 2, n=111);
U.S. Loma Linda
Median 48 months 4 years: 51 GyE 18%, 60 GyE
32%, 70 Gy 51%
4 years: 60 GyE 45%,
70 Gy 74%
4 years
peripheral T1:
81%
NR Rib fractures: 3.6%, no other ≥G2
adverse events
4 years OS peripheral T1: 60% Peripheral T1: 96%
Kanemoto et al. (19) (retrospective,
n=74, 80 tumors), Japan, Tsukuba
Median 31 months
(range 7.3–104.3)
3 years 76.7%, 5 years 65.8% 3 years 81.8%, 5 years
81.8%
NR 3 years 58.6%,
5 years 52.5%
Acute: G2 skin: 2.5%, G2 esophagitis:
1.3%, G3 pneumonitis: 1.3%
3 years Stage IA
86.2%, IB 67%
Late: G3 RP: 1.3%, G3 skin ulcer
1.3%, G4 rib fracture 13.8%
C-ION (COMBINEDWITH PROTON BEAM)
Iwata et al. (24) (retrospective,
n=80), Japan, Hyogo
Median 30.5 months
(range 18–66)
3 years 75% (Stage IA 74%,
IB 76%)
3 years 82% (Stage IA
87%, IB 77%)
16%a 3 years 54% (Stage
IA 67%, IB 46%)
Lung toxicity: G2 RP: 11%, G3 RP:
1.3%
3 years OS by dose: 80 GyE
90%, 60 GyE 61%, 52.8 GyE
86%
3 years LC by dose:
80 GyE 83%, 60 GyE
81%, 52.8 GyE 86%
Skin: dermatitis G2/3: 16%
G2 rib fracture: 23%
(Continued)
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Table 3 | Continued
Study (characteristics);
location
FU OS LC DM PFS Toxicity
Iwata et al. (25) {retrospective
[partially subgroup of cohort Iwata
(24)], n=70}, Japan, Hyogo
Median 51 months
(range 24–103)
4 years 58% (T2a 53%, T2b
67%)
4 years 75% (T2a
70%, T2b 84%)
20%a 4 years 46% (T2a
43%, T2b 52%)
G2/3 radiation pneumonitis 3%,
G2/3/4 dermatitis 7%, Rib fracture G2
27%, soft tissue fibrosis G2 6%Operable patients (n=30):
4 years 72%
Operable patients
(n=30): 4 years 73%
Operable patients
(n=30): 4 years 46%
Miyamoto et al. (20) (phase I/II,
n=81, 82 tumors), Japan, Chiba
Median 52.6 months 5 years 42% (Stage IA 64.4%,
Stage IB 22%)
23% local recurrence
at 6.2–27.2 months
after start RT
38% NR Acute: lung G2: 6.2%, G3: 3.7%
Late: lung G2: 1.2%
Miyamoto et al. (21) (phase II,
n=79), Japan, Chiba
Median 38.6 months
(range 2.5–72.2)
5 years 45% (Stage IA: 62%,
IB 25%)
5 years 90% (Stage IA
98%, IB 80%)
27%a NR Acute: lung G2: 1.3%
Late: lung G2: 1.3%
No G3 toxicity
Miyamoto et al. (22) (phase II,
n=50, 51 tumors), Japan, Chiba
Median 59.2 months
(range 6–83)
5 years 50% (Stage IA 55.2%,
IB 42.9%)
5 years 95% 28%a NR Acute: lung toxicity: G1: 2%, G2: 2%.
Skin G1: 100%
Late: lung G1: 96%, G2: 4%. Skin
G1: 98%
Sugane et al. (23) (phase II, n=28,
29 tumors), Japan, Chiba
NR 2 years 64.3%, 5 years 30.7%
(Stage IB 21.2%)
2 and 5 years: 95.8%
(Stage IA 100%, IB
91.7%). Tumor >4 cm:
5 years LC 80%
NR Acute: no lung toxicity. Skin G1: 96%
Late: lung toxicity G1: 96%. Skin G1:
100%
aOwn calculation, time-point unknown.
DM, distant metastases; FU, follow-up; G, CTC Grade; LC, local control; NR, not reported; OS, overall survival; PFS, progression free survival; RP, radiation pneumonitis; RT, radiotherapy.
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Table 4 | Study outcomes advanced-stage NSCLC.
Study (characteristics); location FU OS LC DM PFS Toxicity
PROTON BEAM ONLY
Bush et al. (26) (prospective,
n=35); U.S. Loma Linda
Median 14 months
(range 3–45)
2 years 31% (IIIA 13%) 2 years 87% 14%a 2 years 63% (IIIA
19%)
G2 RP: 5.7%
Shioyama et al. (27) (retrospective,
n=51); Japan, Tsukuba
Median 30 months
(range 18–153)
2 years 62%, 5 years 29% 5 years 57% (total
group)
16%a 5 years 37% (total
group)
Acute: lung tox ≤G1: 92%, G2: 6%,
G3: 2%2 years Stage III/IV 62%,
5 years Stage III/IV 0%
Chang et al. (32) (phase II, n=44),
U.S., Houston
Median 19.7mnd
(range 6.1–44.4)
1 year 86% Local recurrence rate
20.5%
43% 1 year 63% Acute: CT related G4 tox: 11.4%. G3
dermatitis: 11.4%, G3 esophagitis:
11.4%, G3 RP: 2.3%. No G4 toxicity
Late: pulmonary/pleural fistula: 2.3%
Nakayama et al. (31) (retrospective,
n=35), Japan, Tsukuba
NR 1 year 81.8%, 2 years 58.9% 1 year 93.3%, 2 years
65.9%
20% 1 year 59.6%,
2 years 29.2%
Lung: G1: 25.7%, G2: 14.3%. G2
esophagitis: 2.9%. No ≥G3 toxicity
Xiang et al. (34) (prospective,
n=84), U.S. Houston
Median 19.2 months
(6.1–52.4)
3 years 37.2% 2 years 83% 39% 3 years
DMFS 35.4%
3 years 31.2% NR
Oshiro et al. (30) (retrospective,
n=57), Japan, Tsukuba
Median 16.2 months 1 year 65.5%, 2 years 39.4% 1 year 79.1%, 2 years
64.1%
47%a 1 year 36.2%,
2 years 24.9%
Acute: lung (RP) G2: 7%, G3: 1.8%,
G4: 1.8%, G5: 1.8%. Esophagitis G2:
1.8%
Late: RP G2: 6.3%. Hemoptysis G5:
2.1%
aOwn calculation, time-point unknown.
DM, distant metastases; DMFS, distant metastasis free survival; FU, follow-up; G, CTC Grade; LC, local control; NR, not reported; OS, overall survival; PFS, progression free survival; RP, radiation pneumonitis;
RT, radiotherapy.
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Wink et al. Review particle therapy in lung tumors
patients (35%) developed a regional recurrence, and 7 patients
(20%) developed distant metastases. Chang et al. (32) added
concurrent chemotherapy to PBT and reported overall and
progression-free survival of 86 and 63%, respectively, at 1 year,
and a median OS time of 29.4 months. Again, distant metastases
were the most frequent site of failure (19 patients, 43%). Only
four patients (9.1%) had an isolated local recurrence. OS and
progression-free survival (PFS) were better than those reported
by Oshiro et al. (30), possibly due to the added effects of the
concurrent chemotherapy or the pretreatment condition of the
patients. While the patients included by Chang et al. (32) were
fit enough to receive (concurrent) chemotherapy, most of those
described by Oshiro et al. (30) were not (mostly due to old
age and comorbidities). In an updated analysis of an expanded
cohort of 84 patients treated at MD Anderson Cancer Center
with concurrent chemotherapy and PBT for locally advanced
NSCLC that assessed the correlation between post-treatment FDG
uptake on PET/CT scan and clinical outcomes, including sur-
vival, Xiang et al. (34) reported a similar median survival time of
29.9 months. At 3 years, the local recurrence-free survival (LRFS)
rate was 34.8%, distant metastasis-free survival (DMFS) rate was
35.4%, PFS rate was 31.2%, and the OS rate was 37.2%. Further-
more, post-treatment SUV was found on multivariate analysis
to be independently prognostic for LRFS, DMFS, PFS, and OS
(all p< 0.05).
Toxicity. Acute treatment toxicity was generally mild. Oshiro
et al. (30) reported Grade≥ 3 lung toxicity in three patients (5%):
one patient had Grade 3 pneumonitis effectively treated with
steroids, one patient had to discontinue treatment due to Grade 4
pneumonitis, and one patient died of pneumonitis during treat-
ment (Grade 5). Both patients with the severe pneumonitis had
severe preexisting interstitial pneumonitis prior to the diagno-
sis of NSCLC and, therefore, were deemed unsuitable for surgery
or conventional (photon) radiotherapy. Three patients developed
Grade≥ 3 late toxicity: two patients with Grade 3 dyspnea, and
one patient with Grade 5 hemoptysis (after repeated biopsy of the
irradiated bronchus).
In the study by Chang et al. (32), toxicity was primarily related
to the administered chemotherapy and consisted mainly of Grade
2 and 3 bone marrow suppression. A further five patients (11.4%)
experienced Grade 3 esophagitis, one patient (2.3%) developed
Grade 3 pneumonitis, and five patients (11.4%) had Grade 3
dermatitis. One patient developed a pulmonary/pleural fistula.
No Grade 5 toxicity occurred. Toxicity was not reported in the
expanded analysis by Xiang et al. Nakayama et al. (31) reported no
Grade≥ 3 toxicities.
PROTON THERAPY TECHNIQUES AND CONSIDERATIONS FOR
TREATMENT PLANNING AND DELIVERY
Protons can be delivered with two different radiation techniques:
passive scattering proton therapy (PSPT) or PBS. In PSPT, the
tumor volume is irradiated as a whole, using collimators and
compensators for dose conformality. With PBS, the target vol-
ume is scanned spot-by-spot with a narrow proton beam, enabling
intensity-modulated proton therapy (IMPT). Most institutions
treating NSCLC with protons use the passive technique as it is
the most widely available and moreover less sensitive to breathing
motion than PBS.
Matney et al. (35) quantified and compared the effects of res-
piratory motion on clinically delivered IMRT and re-calculated
PSPT plans for 20 stage II-IIIb NSCLC patients. For a respiratory
motion of up to 17 mm, target coverage was maintained for both
IMRT and PSPT. Only two of the studied comparative parameters,
lung V5 and spinal cord Dmax, were statistically significantly bet-
ter when using PSPT. The authors concluded that PSPT may not
be more susceptible to respiratory motion than IMRT.
Passive scattering proton therapy also leads to a non-conformal
dose distribution at the proximal edge of the field. Conformal-
ity is better for the PBS technique, but the interplay between the
intrafractional tumor motion and the scanned proton beams can
have detrimental effects on the dose distribution. This so-called
“interplay effect” can result in severe under- or overdosage: a spot
can be irradiated several times or not at all. Thus, the dose is not
only inhomogeneous at the edges but also inside the target, and
therefore, cannot be accounted for by simply adding a surrounding
margin (36). This is crucial especially for full IMPT that, in con-
trast to the single field uniform dose (SFUD) technique, results
in completely inhomogeneous dose distributions per field. To our
knowledge, only the MD Anderson Cancer Center has started to
treat NSCLC with PBS using the SFUD technique, limiting the
treatment to a subset of tumors with motion amplitudes below
5 mm. Li et al. (37) investigated the extent of the interplay effect
on IMPT delivery and concluded that for the specific system at
MDACC, the this effect may not be a primary concern. Grass-
berger et al. (38) and Dowdell et al. (39) have reported that the
magnitude of the interplay effect depends on patient parameters
such as motion amplitude and beam delivery parameters such as
spot size. Several techniques (rescanning, gating, tracking) try-
ing to compensate for the interplay effect are topic of intensive
research in several groups worldwide. For IMPT, the robustness
and a geometrical tumor tracking method mitigating to motion
were evaluated in 7 NSCLC patients treated to 45 GyE in 3 fractions
(40). Patients had in total nine peripheral stage I lung tumors that
were imaged with 4D-CT, and the combined dose distribution was
summed using deformable image registration. Additionally, plans
were constructed in which the proton beams were geometrically
shifted without adjusting the beam energy. In 6 tumors show-
ing a displacement of <1 cm, 97–100% of the GTV was covered
by 95% of the prescribed dose. For the remaining three patients,
this was 95, 82, and 51%, respectively; subsequently, the appli-
cation of a geometrical tracking method improved this to 100,
98, and 97%, respectively. The authors concluded that the simple
tracking method was valuable for improving GTV coverage. The
practicalities and limitations of tracking and gating techniques
in IMPT have also been reported by the group at Paul Scherrer
Institute (41, 42).
Another key aspect is plan robustness, meaning the suscepti-
bility of the nominal treatment plan due to uncertainties (e.g.,
setup uncertainties) or motion. Some treatment planning systems
already allow the evaluation of plan robustness. Furthermore, con-
sideration of robustness can not only be included in the treatment
plan evaluation step but also in the plan optimization (robust opti-
mization) (43–46). Usually, this will result in decreased quality of
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the nominal treatment plan in combination with smaller devi-
ations between nominal and actual dose distribution under the
influence of setup uncertainties and intra- and interfractional
motion.
For PSPT, range and setup uncertainties can be taken into
account by widening the aperture to ensure the lateral coverage in
the presence of setup and/or in-patient target shifts. Furthermore,
density changes lateral to the beam path, e.g., due to intrafractional
motion, are mitigated by “smearing” the compensator. Range
uncertainties are accounted for by increasing the nominal range.
This method was investigated by several groups (9, 47) and is
widely accepted in PSPT in the clinic (8, 48–50).
For PBS, no physical devices are used. Consequently, a different
method needs to be applied to compensate for range and setup
uncertainties. Laterally, an increased treatment area adding a mar-
gin to the tumor volume is applicable. For range uncertainties,
a more sophisticated approach is the use of field-specific PTVs
that take into account the influences of range uncertainty for each
treatment field separately (10, 51, 52). In comparison to a uniform
margin extension, this leads to a PTV that can compensate for
the specific requirements in proton therapy and thus preserves the
target coverage in the presence of uncertainties.
(IN SILICO) COMPARATIVE STUDIES
Various institutions employing particle therapy or in the process
of setting up the facility have published findings on comparative
in silico planning studies using different photon and proton deliv-
ery techniques. Kase et al. (53) compared PSPT with IMPT in a
variety of primary tumor sites, including NSCLC. IMPT resulted
in lower dose to organs at risk, specifically, the high dose to the
skin, the D20 to the normal lung, and the spinal cord.
Early-stage NSCLC. Wang and colleagues (54) from the Pro-
ton Medical Research Center compared 3D-CRT to PSPT in 24
patients with peripheral stage I NSCLC. Two to four proton beam
ports were used and irradiation was applied at end exhalation.
Photons were delivered using 5 to 7 coplanar ports covering the
same clinical and planning target volume (CTV and PTV, respec-
tively). The prescribed dose was 66 GyE in 10 fractions at the
isocenter. While the 90% isodose line covered >99% of the CTV
for both treatment modalities, the 95% isodose line covered only
86.4% of the CTV for proton plans and 43.2% for 3D-CRT plans.
Organ at risk (OAR) doses, specifically, lungs, heart, esophagus,
and spinal cord, were significantly lower for the proton beam
technique.
The Mayo Clinic Group (55) generated treatment plans for
eight stage I NSCLC patients with peripheral lung nodules using
photon SBRT, and one-, two-, and three-field passively scattered
or actively scanned proton beams. For SBRT (3× 20 Gy), 10 or
more non-coplanar beams were manually selected to achieve opti-
mal PTV coverage while minimizing dose to the OARs. Plans were
normalized to isocenter with the prescription isodose line covering
95% or more of the PTV. For proton beam treatment, beam direc-
tion was manually optimized to maximize access to the tumor,
while minimizing exposure to OARs and adjacent normal tissues.
Proton beam plans demonstrated significantly lower maximum
and higher minimum PTV doses compared with SBRT. With the
exception of the three-field actively scanned approach, the maxi-
mum dose 2 cm from the PTV was significantly higher with proton
beams. The doses to OARs (lungs, spinal cord,heart,bronchial tree,
esophagus, skin, and ribs) were generally lower with protons than
with photons. Using actively scanned beams, the maximum dose
to the PTV, V30Gy, and the dose to any tissue 2 cm from the PTV
decreased, while the minimum dose to the PTV increased.
Similarly, Kadoya et al. (56) studied 21 patients with peripheral
stage I NSCLC, delivering a dose of 66 GyE in 10 fractions during
maximal expiration using SBRT (7–8 non-coplanar 4-MV photon
beams) or PSPT (2–3 directions). While the dose to the PTV was
non-significantly different, the dose to the lung was significantly
lower with the PSPT technique. The authors concluded that PSPT
may be advantageous for large or multiple PTVs.
For stage I NSCLC, PBT may provide the greatest dosimetric
and clinical benefit for patients with centrally located tumors given
the higher reported toxicity when delivering SBRT for tumors in
this region. For centrally and superiorly located stage I NSCLC,
Register et al. (57) compared SBRT with PSPT and IMPT. SBRT
was prescribed to 50 Gy in 12.5-Gy fractions, normalized such that
95% of the PTV received 100% of the prescribed dose. Each PSPT
plan was created with three to four coplanar beam angles in an
attempt to minimize the exit dose into the lung parenchyma. The
same beam angels were used for generating the IMPT plans. Only
6 of 15 photon SBRT plans satisfied PTV coverage and all normal
tissue dose constraints, compared to 12 PSPT and 14 IMPT plans.
A significant reduction in the normal tissue dose by passively
scattered protons (66 GyE) compared to 3D-CRT or IMRT photon
treatment (66 Gy) was reported by Chang et al. (58) for stage I and
stage IIIA/B NSCLC patients. For early-stage NSCLC (n= 10), the
DVH comparison revealed a reduction in dose to the ipsilateral
and contralateral lungs, heart, spinal cord, and esophagus with
protons. For locally advanced patients (n= 15) in all cases, the
doses to lung, heart, esophagus, spinal cord, and integral dose were
lower with proton therapy than both 3D-CRT and IMRT photon
modalities. This dosimetric benefits of protons over photons per-
sisted even when escalating the PBT doses to 87.5 GyE for stage I
NSCLC and 74 GyE for stage III NSCLC compared with 66 Gy for
all photon plans.
An in silico planning study comparing modern photon tech-
niques with protons and carbon ions in 25 stage I NSCLC
patients is currently being conducted by the ROCOCO consortium
(NCT02038413).
Locally advanced NSCLC. Proton beam therapy may be advan-
tageous for locally advanced NSCLC patients delivering either
the same dose with less toxicity or a higher dose under isotoxic
conditions. Representative images showing plan comparisons for
patients with locally advanced NSCLC are shown in Figures 1
and 2. In the first, PSPT spares significant volumes of heart, esoph-
agus, and lung relative to IMRT. In the latter comparing IMRT,
PSPT, and PBS using SFUD, the dose to the heart, spinal cord, and
contralateral lung is significantly reduced using (advanced) proton
techniques.
The MD Anderson Cancer Center conducted a prospective
phase II clinical study combining chemotherapy with PSPT in 44
unresectable NSCLC patients (details and outcome of the study
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FIGURE 1 |Treatment planning images and dose–volume histogram
comparison (Hospital of the University of Pennsylvania). Representative
treatment planning images for a patient with locally advanced non-small cell
lung cancer with a right lower lobe primary tumor (iGTV primary tumor
depicted as a yellow contour) and multi-station mediastinal nodal metastasis
(Continued)
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FIGURE 1 | Continued
(iGTV nodal metastasis depicted as a yellow contour). The composite PTV
is depicted as a cyan contour. Comparative plans for IMRT (left) and proton
beam therapy (right) are depicted in the axial planes (top row), sagittal
planes (middle row), and coronal planes (bottom row) delivering 66.6 Gy
(IMRT) or 66.6 GyE (proton therapy) in 37 fractions. Dose color wash
coding: blue=50% to red=global max above 100%. Representative
dose–volume histograms for the same patient are also depicted showing
dose to target volumes of PTV (green) and ITV (cyan) and dose to normal
structures of heart (orange), total lung minus GTV (purple), esophagus
(light blue), and spinal cord (dark blue) for IMRT (triangle) and proton
(square) plans.
FIGURE 2 |Treatment plan comparison between IMRT (left upper row),
PSPT (right upper row) and PBS using SFUD (left lower row) in an
advanced-stage NSCLC patient (OncoRay, Dresden). The planning target
volume (PTV) is represented by the white contour. Furthermore a
dose–volume histogram (DVH; right lower row) analysis is illustrated for the
three treatment techniques showing the clinical target volume (CTV; red), PTV
(dark red), ipsilateral lung (blue), spinal cord (orange), heart (pink), and
contralateral lung (turquois).
described earlier (32). Koay et al. (33) published an analysis for
the nine out of 44 patients for whom the plans were adapted dur-
ing the treatment course. While the authors observed profound
differences in the dose to the esophagus and spinal cord, no sta-
tistical comparison of the adapted versus non-adapted patients
was performed. For two of the nine patients, the internal CTV
coverage would have decreased significantly without adaptation.
Remarkably, the reported toxicity was higher among the patients
treated with adaptive plans, although statistical comparison was
again lacking. Treatment outcome was not significantly different
between the treatment strategies (p> 0.05).
Zhang et al. (59) compared IMPT with PSPT and IMRT in 20
NSCLC patients with extensive stage IIIB disease. Using IMRT,
the selected patients had no or borderline tolerance to IMRT
at 60–63 Gy when keeping within the normal tissue dose con-
straints. IMPT succeeded in sparing more lung, heart, spinal cord,
and esophagus when maintaining the prescribed dose. IMPT was
even feasible when escalating the dose up to 83.5 Gy (mean max-
imum tolerated dose 74 Gy), whereas PSPT was limited by the
esophagus dose constraint (74 Gy). The University of Florida Pro-
ton Therapy Institute (60) compared 3D-CRT with IMRT and
PSPT in eight NSCLC patients. The target dose prescription was
achieved in all patients using either of the techniques. Compared
to the photon techniques, PSPT considerably reduced the dose
to radiation-sensitive normal structures: normal lung V20Gy by
median 29% for 3D-CRT and 26% for IMRT, mean lung dose by
33 and 31%, and V10Gy bone marrow by 30 and 27%, respectively.
This may offer an advantage in patients undergoing sequential or
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concurrent radiochemotherapy. In a multicentric in silico clinical
trial, the ROCOCO consortium compared photon (3D-CRT and
IMRT) with proton (PSPT) treatment for stage IA-IIIB NSCLC
patients delivering 70 Gy in 35 fractions (8). The integral dose for
the photon techniques was higher than for the proton techniques,
whereas the mean lung dose was lower for protons. For 10 patients,
dose escalation to the primary tumor up to 87 Gy was feasible for
all three modalities; however, the mean lung and integral doses
were higher for photons than for protons.
CONCLUSION
Proton beam delivery has evolved rapidly over the last decade,
enabling highly conformal treatment delivery with the possibility
of escalating the dose to the primary tumor while maintaining the
dose to the normal tissues, or maintaining the dose to the target
volume and reducing the dose to the organs at risk. Dosimet-
ric advantages of protons over photons have been demonstrated
across NSCLC stages of disease in reducing doses to critical organs
at risk, including the lungs, heart, esophagus, and spinal cord. PBT
has also been used clinically in an increasing number of prospec-
tive studies for both stage I NSCLC and locally advanced NSCLC
with a generally more favorable toxicity profile than what has been
reported with historical photon studies. Particle beam treatment
may prove to provide its greatest clinical benefit compared with
IMRT and photon treatment techniques for patients with pre-
treatment severe functional impairments (e.g., poor lung function,
preexisting lung disease), when delivering escalating doses of radi-
ation therapy or using radiation therapy as part of trimodality
therapy combined with chemotherapy and surgery, and for defin-
itive re-treatment of NSCLC patients with a local/locoregional
recurrence following prior radiotherapy. From the in silico trials
we have gathered, we can conclude that the dose distributions
with IMPT are superior to those of the photon treatments and
the passive scattering technique. Until now, PSPT has predomi-
nantly been used in the clinic instead of IMPT. It is likely that
a more widespread introduction of IMPT can provide further
improvement in lung cancer outcome and/or decreased toxicity,
through increased precision and personalized treatment, provided
that range uncertainties are well accounted for.
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